Champions Oncology (NASDAQ:CSBR) Announces Earnings Results

Champions Oncology (NASDAQ:CSBR) announced its quarterly earnings data on Monday. The biotechnology company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06, FiscalAI reports. Champions Oncology had a negative return on equity of 27.51% and a negative net margin of 1.87%.The firm had revenue of $13.84 million during the quarter, compared to analyst estimates of $12.89 million.

Here are the key takeaways from Champions Oncology’s conference call:

• Champions Oncology reported record fiscal 2026 revenue of $59.4 million, up 12%, driven by 12% growth in Study Services to $58.7 million.
• The company achieved its goal of positive adjusted EBITDA, posting $1.6 million for the year and positive adjusted EBITDA in all four quarters for the first time since fiscal 2022.
• Gross margin improved to 51% in the fourth quarter as the company reduced outsourced radiopharmaceutical costs by bringing more work in-house, a shift management expects to support further margin gains.
• Data-license revenue fell to approximately $800,000 from $4.7 million because a large prior-year transaction did not recur, although some expected revenue shifted into fiscal 2027 and the customer pipeline expanded.
• Management remains encouraged by Corellia’s therapeutic data and is pursuing venture funding or a pharmaceutical licensing partnership; however, no specific timing was provided, and the company plans to fund the subsidiary internally for fiscal 2027 if necessary.

Champions Oncology Price Performance

Champions Oncology stock opened at $5.53 on Wednesday. The company has a market capitalization of $76.81 million, a price-to-earnings ratio of -69.12 and a beta of 0.39. The company’s fifty day moving average price is $6.05 and its two-hundred day moving average price is $6.17. Champions Oncology has a one year low of $5.39 and a one year high of $8.74.

Institutional Investors Weigh In On Champions Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in CSBR. XTX Topco Ltd bought a new stake in Champions Oncology during the second quarter worth approximately $103,000. Essex Investment Management Co. LLC bought a new position in shares of Champions Oncology in the fourth quarter valued at approximately $126,000. Jane Street Group LLC acquired a new stake in shares of Champions Oncology in the first quarter worth $200,000. Goldman Sachs Group Inc. acquired a new stake in shares of Champions Oncology in the first quarter worth $201,000. Finally, Acadian Asset Management LLC lifted its stake in shares of Champions Oncology by 28.7% in the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock worth $341,000 after buying an additional 8,814 shares during the last quarter. 41.30% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Champions Oncology Company Profile

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.